-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Shijiazhuang Sihua Pharmaceutical Group Has Been Approved to Conduct Bioequivalence Studies and Clinical Trials for Type 2 Diabetes Involving Trogliptin Succinate Tablets
Category:
发布时间：2023-11-23
【概要描述】
On November 23, Shijiazhuang Sihua Pharmaceutical Group received approval from the National Medical Products Administration to conduct bioequivalence studies and clinical trials for type 2 diabetes involving trigratine succinate tablets.
On November 23, Shijiazhuang Sihua Pharmaceutical Group received approval from the National Medical Products Administration to conduct bioequivalence studies and clinical trials for type 2 diabetes involving troglitazone succinate tablets.
According to available information, ambrisentan succinate tablets are a long-acting, selective dipeptidyl peptidase-4 (DPP-4) inhibitor that requires only once-weekly dosing to provide selective and sustained DPP-4 inhibition. Ambrisentan succinate tablets can be used as monotherapy or in combination with other oral antihyperglycemic agents, offering unique advantages such as a low risk of hypoglycemia, no weight gain, minimal adverse effects, and, notably, a low incidence of gastrointestinal adverse reactions.
Over the past two years, Shijiazhuang Sihua Pharmaceutical has steadfastly pursued an innovation-driven development strategy, concentrating its strengths on tackling key scientific and technological challenges in the areas of innovative drugs, shortage medications, and treatments for rare diseases. The company has continuously accelerated its strategic planning and deployment in complex formulations, improved new drugs, and innovative medicines, thereby powerfully advancing the enterprise’s value chain toward the mid- to high-end segment.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091